



Hier finden Sie eine Zusammenstellung der Veröffentlichungen von **Mitarbeiterinnen und Mitarbeitern** des BfArM aus dem Jahr 2020

Originalarbeiten, referiert

Arshaad MI, Siwek M, Henseler C, Daubner J, Ehninger D, Hescheler J, Sachinidis A, Broich K, Papazoglou A, Weiergräber M (2020) Enhanced hippocampal type II theta activity and altered theta architecture in mice lacking the Cav3.2 T-type voltage-gated calcium channel. *Sci Rep* in press

Baldacci F, Lista S, Manca ML, Chiesa PA, Cavedo E, Lemercier P, Zetterberg H, Blennow K, Habert MO, Potier MC, Dubois B, Vergallo A, Hampel H, INSIGHT-preAD study group, Alzheimer's Precision Medicine Initiative (APMI) (... **Haenisch B** ...) (2020) Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. *Alzheimers Res Ther* 12(1):147

Barakat AK, Scholl C, Steffens M, Brandenburg K, Ising M, Lucae S, Holsboer F, Laje G, Kalayda GV, Jaehde U, Stingl JC (2020) Citalopram-induced pathways regulation and tentative treatment-outcome-predicting biomarkers in lymphoblastoid cell lines from depression patients. *Transl Psychiatry* 10(1):210, <https://doi.org/10.1038/s41398-020-00900-8>

Barth U (2020) LAA-Okkluder versus orale Antikoagulation bei nonvalvulärem Vorhofflimmern in klinischen Studien: Wie ist die Evidenz? *Der Kardiologe* 14(4):298-315, doi 10.1007/s12181-020-00397-x

Benda N, Haenisch B (2020) Enrichment design using placebo non-responders. *Pharm Stat* 19(3):303-314

Coleman JRI, Gaspar HA, Bryois J, Bipolar Disorder Working Group of the Psychiatric Genomics Consortium, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium (... **Steffens M** ...), Breen G (2020) The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls. *Biol Psychiatry* 88(2):169-184

Danese S, **Schabel E**, Ainsworth MA, Peyrin-Biroulet L (2020) Challenges and opportunities for IBD drug development: from early stage to regulatory approval. *Gut* 69(7):1157-1161

Dubrall D, Just K, Schmid M, Stingl JC, **Sachs B** (2020) Adverse drug reactions in older adults: a retrospective comparative analysis of spontaneous reports to the German Federal Institute for Drugs and Medical Devices. *BMC Pharmacol Toxicol* 21(1):25



Dubrall D, Schmid M, Stingl JC, **Sachs B** (2020) Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports. *PLoS One* 15(3):e0230632

Gaebler AJ, **Schneider KL**, Stingl JC, Paulzen M (2020) Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status. *Pharmacogenomics J* 20(6):840-844

Hübner T, **Steffens M**, Linder R, **Fracowiak J**, Langner D, Garling M, Heilmann T, Roethlein C, Gomm W, **Haenisch B**, Stingl JC (2020) Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR. *BMJ Open* 10(4):e032624

Just KS, Dormann H, **Böhme M**, **Schurig M**, Schneider K, **Steffens M**, **Dunow S**, Plank-Kiegele B, Ettrich K, Seufferlein T, Gräff I, Igel S, Schrickler S, Jaeger S, Schwab M, Stingl JC (2020) Personalising drug safety – results from the multi-centre prospective observational study on adverse drug reactions in emergency departments (ADRED). *Eur J Clin Pharmacol* 76(3):439-448

Just KS, Dormann H, **Schurig M**, **Böhme M**, **Fracowiak J**, **Steffens M**, **Scholl C**, Seufferlein T, Gräff I, Schwab M, Stingl JC (2020) Adverse Drug Reactions in the Emergency Department: Is There a Role for Pharmacogenomic Profiles at Risk? - Results from the ADRED Study. *J Clin Med* 9(6):1801, <https://doi.org/10.3390/jcm9061801>

Just KS, Dormann H, **Schurig M**, **Böhme M**, **Steffens M**, Plank-Kiegele B, Ettrich K, Seufferlein T, Gräff I, Igel S, Schrickler S, Jaeger SU, Schwab M, Stingl JC (2020) The phenotype of adverse drug effects: Do emergency visits due to adverse drug reactions look different in older people? Results from the ADRED study. *Br J Clin Pharmacol* 86(11):2144-2154

Kaina B, Beltzig L, Piee-Staffa A, **Haas B** (2020) Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells. *Int J Mol Sci* 21(19):7006, doi:10.3390/ijms21197006

Kesselmeier M, **Benda N**, Scherag A (2020) Effect size estimates from umbrella designs: Handling patients with a positive test result for multiple biomarkers using random or pragmatic subtrial allocation. *PLoS One* 15(8):e0237441



Lundt A, Soos J, Seidel R, Henseler C, Müller R, Raj Ginde V, Arshaad MI, Ehninger D, Hescheler J, Sachinidis A, Broich K, Wormuth C, Papazoglou A, Weiergräber M (2020) Functional implications of Cav 2.3 R-type voltage-gated calcium channels in the murine auditory system – novel vistas from brainstem-evoked response audiometry.

Eur J Neurosci 51(7):1583-1604

Möltgen S, Piumatti E, Massafra GM, Metzger S, Jaehde U, **Kalayda GV** (2020) Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity.

Cells 9(6):E1322, doi: 10.3390/cells9061322

Muders T, Luepschen H, Meier T, Reske AW, **Zinserling J**, Kreyer S, Pikkemaat R, Maripu E, Leonhardt S, Hedenstierna G, Putensen C, Wrigge H (2020) Individualized Positive End-expiratory Pressure and Regional Gas Exchange in Porcine Lung Injury.

Anesthesiology 132(4):808-824

Mütze T, Salem S, **Benda N**, Schmidli H, Friede T (2020) Blinded continuous information monitoring of recurrent event endpoints with time trends in clinical trials.

Stat Med 39(27):3968-3985

Nerius M, **Haenisch B**, Gomm W, Doblhammer G, Schneider A (2020) Glucocorticoid Therapy is Associated with a Lower Risk of Dementia.

J Alzheimers Dis 73(1):175-183

Noureddin M, Chan JL, Barradas K, Dimick-Santos L, **Schabel E**, Omokaro SO, Anania FA, Myers RP, Miller V, Sanyal AJ, Chalasani N (2020) Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum.

Gastroenterology 159(2):422-427 e1

Prus M, **Benda N**, Schwabe R (2020) Optimal Design in Hierarchical Random Effect Models for Individual Prediction with Application in Precision Medicine.

J Stat Theory Pract 14(2):24

Schneider KL, Kunst M, Leuchs AK, Böhme M, Weckbecker K, Kastenmüller K, Bleckwenn M, Holdenrieder S, Coch C, Hartmann G, Stingl JC (2020) Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms.

Front Pharmacol 10:1620

Stallard N, Hampson L, **Benda N**, Brannath W, Burnett T, Friede T, Kimani PK, Koenig F, Krisam J, Mozgunov P (2020) Efficient adaptive designs for clinical trials of interventions for COVID-19.

Stat Biopharm Res 12(4):483-497



Stingl JC, Just KS, **Schurig M, Böhme M, Steffens M**, Schwab M, Seufferlein T, Dormann H (2020) Prevalence of Psychotropic Drugs in Cases of Severe Adverse Drug Reactions Leading to Unplanned Emergency Visits in General Hospitals. *Pharmacopsychiatry* 53(3):133-137, doi:10.1055/a-1110-1010

Tabari D, Scholl C, Steffens M, Weickhardt S, Elgner F, Bender D, Herrlein ML, Sabino C, Semkova V, Peitz M, Till A, Brüstle O, Hildt E, Stingl J (2020) Impact of Zika Virus Infection on Human Neural Stem Cell MicroRNA Signatures. *Viruses* 12(11):1219, doi:10.3390/v12111219

Vergallo A, Lista S, Lemercier P, Chiesa PA, Zetterberg H, Blennow K, Potier MC, Habert MO, Baldacci F, Cavedo E, Caraci F, Dubois B, Hampel H, INSIGHT-preAD study group, Alzheimer's Precision Medicine Initiative (APMI) (... **Haenisch B** ...) (2020) Association of plasma YKL-40 with brain amyloid- β levels, memory performance, and sex in subjective memory complainers. *Neurobiol Aging* 96:22-32

Viviani R, Dommes L, Bosch J, **Steffens M, Paul A, Schneider KL**, Stingl JC, Beschoner P (2020) Signals of anticipation of reward and of mean reward rates in the human brain. *Sci Rep* 10(1):4287

Viviani R, Messina I, Bosch JE, Dommes L, **Paul A, Schneider KL, Scholl C**, Stingl JC (2020) Effects of genetic variability of CYP2D6 on neural substrates of sustained attention during on-task activity. *Transl Psychiatry* 10(1):338, doi:10.1038/s41398-020-01020-z

Wester P, Möselers BM, **Knöss W** (2020) Intra-population terpene polymorphism of *Thymus pulegioides* L.: Evidence for seven chemotypes in a German limestone grassland. *Biochem Syst Ecol* 93:104173

Zapf A, Stark M, Gerke O, Ehret C, **Benda N**, Bossuyt P, Deeks J, Reitsma J, Alonzo T, Friede T (2020) Adaptive trial designs in diagnostic accuracy research. *Stat Med* 39(5):591-601

Letter/Correspondence

Glässner A, Krämer C, Sachs B (2020) Letter to the editor concerning "A novel whole blood based method for lymphocyte transformation test in drug allergies" [Letter]. *J Immunol Methods* available online 26 June 2020, doi.org/10.1016/j.jim.2020.112815



Reviews, referiert

Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, Donaldson E, Westman G, **Buchholz S**, Miller V, Hansen BE (2020) Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis.

Clin Gastroenterol Hepatol S1542-3565, doi: 10.1016/j.cgh.2020.05.041

Babiloni C, Blinowska K, Bonanni L, Cichocki A, De Haan W, Del Percio C, Dubois B, Escudero J, Fernandez A, Frisoni G, Guntekin B, Hajos M, Hampel H, Ifeachor E, Kilborn K, Kumar S, Johnsen K, Johannsson M, Jeong J, LeBeau F, Lizio R, Lopes da Silva F, Maestu F, McGeown WJ, McKeith I, Moretti DV, Nobili F, Olichney J, Onofri M, Palop JJ, Rowan M, Stocchi F, Struzik ZM, Tanila H, Teipel S, Taylor JP, **Weiergräber M**, Yener G, Young-Pearse T, Drinkenburg WH, Randall F (2020) What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons.

Neurobiol Aging 85:58-73

Cornberg M, Lok AS, Terrault NA, Zoulim F, 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty (Berg T, Brunetto M, **Buchholz S**, Buti M, Chan H et al.) (2020) Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.

Hepatology 71(3):1070-1092

Cornberg M, Lok AS, Terrault NA, Zoulim F, 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty (Berg T, Brunetto M, **Buchholz S**, Buti M, Chan H et al.) (2020) Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.

J Hepatol 72(3):539-557

Daubner J, **Arshaad MI**, **Henseler C**, Hescheler J, Ehninger D, **Broich K**, Rawashdeh O, **Papazoglou A**, **Weiergräber M** (2020) Pharmacological Neuroenhancement - Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics and Future Perspectives. *Neural Plast* in press

Eichler HG, Cavaleri M, **Enzmann H**, Scotti F, Sepodes B, Sweeney F, Vamvakas S, Rasi G (2020) Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?

Clin Pharmacol Ther 108(4):730-733

Eichler HG, Koenig F, Arlett P, **Enzmann H**, Humphreys A, Pétavy F, Schwarzer-Daum B, Sepodes B, Vamvakas S, Rasi G (2020) Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation.

Clin Pharmacol Ther 107(4):773-779



Elliott P, Cowie MR, Franke J, Ziegler A, Antoniadis C, Bax J, Bucciarelli-Ducci C, Flachskampf FA, Hamm C, Jensen MT, Katus H, Maisel A, McDonagh T, **Mittmann C**, Muntendam P, Nagel E, Rosano G, Twerenbold R, Zannad F (2020) Development, validation and implementation of biomarker testing in cardiovascular medicine state-of-the-art: Proceedings of the European Society of Cardiology - Cardiovascular Round Table.
Cardiovasc Res doi: 10.1093/cvr/cvaa272, Epub ahead of print

Fischer T (2020) Das Data Monitoring Committee – State of the Art und Perspektiven für die Zukunft.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz:1-8, Epub ahead of print, doi: 10.1007/s00103-020-03212-w

Glass O, Filozof C, Nouredin M, Berner-Hansen M, **Schabel E**, Omokaro SO, Schattenberg JM, Barradas K, Miller V, Francque S, Abdelmalek MF (2020) for the Liver Forum Standard of Care Working Group: Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum.
J Hepatol 73(3):680-693

Guth S, Hüser S, Roth A, Degen G, Diel P, Edlund K, Eisenbrand G, Engel KH, Epe B, Grune T, Heinz V, Henle T, Humpf HU, Jäger H, Joost HG, Kulling SE, Lampen A, Mally A, Marchan R, Marko D, Mühle E, Nitsche MA, **Röhrdanz E**, Stadler R, van Thriel C, Vieths S, Vogel RF, Wascher E, Watzl C, Nöthlings U, Hengstler JG (2020) Toxicity of fluoride: critical evaluation of evidence for human developmental neurotoxicity in epidemiological studies, animal experiments and in vitro analyses.
Arch Toxicol 94(5):1375-1415

Hampel H, Lista S, Vanmechelen E, Zetterberg H, Giorgi FS, Galgani A, Blennow K, Caraci F, Das B, Yan R, Vergallo A, Alzheimer's Precision Medicine Initiative (APMI) (... **Haenisch, B** ...) (2020) β -Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification.
Alzheimers Res Ther 12(1):130

Hampel H, Vergallo A, Caraci F, Cuello AC, Lemercier P, Vellas B, Giudici KV, Baldacci F, **Haenisch B, Haberkamp M, Broich K**, Nistico R, Emanuele E, Llaverro F, Zugaza J, Lucia A, Giacobini E, Lista S (2020) for the Alzheimer Precision Medicine Initiative: Future avenues for Alzheimer's disease detection and therapy: Liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery.
Neuropharmacology 108081, in press

Horn M, Eibenstein G (2020) Lieferengpässe bei Humanarzneimitteln: Rolle des BfArM und Arbeit des Jour fixe "Liefer- und Versorgungsempässe".
Arzneimitteltherapie 38(5):176-182



Kress P, **Pfeiffer K** (2020) Tracheostomaventile und ihre Risiken.

HNO published online 20 July 2020, <https://link.springer.com/article/10.1007/s00106-020-00905-1>

López-Jaramillo C, Díaz-Zuluaga AM, de Leon J, Schoretsanitis G, Paulzen M, Unterecker S, Schwarz M, Conca A, Zernig G, Gründer G, Haen E, Baumann P, Bergemann N, Clement HW, Domschke K, Eckermann G, Egberts K, Gerlach M, **Greiner C**, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud-Sirot E, Messer T, Mössner R, Müller MJ, Pfuhlmann B, Laux G, Riederer P, Saria A, Schoppek B, Silva Gracia M, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zurek G, Hiemke C (2020) Guía de consenso de expertos para la monitorización terapéutica de drogas en neuropsicofarmacología [Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology].

Psiquiatria Biologica 27(3):83-95

Luijten M, Corvi R, Mehta J, Corvaro M, Delrue N, Felter S, **Haas B**, Hewitt NJ, Hilton G, Holmes T, Jacobs MN, Jacobs A, Lamplmair F, Lewis D, Madia F, Manou I, Melching-Kollmuss S, Schorsch F, Schütte K, Sewell F, Strupp C, Willem van der Laan J, Wolf DC, Wolterink G, Woutersen R, Zvonar Z, Heusinkveld H, Braakhuis H (2020) A comprehensive view on mechanistic approaches for cancer risk assessment of non-genotoxic agrochemicals.

Regul Toxicol Pharmacol 118:104789, doi:10.1016/j.yrtph.2020.104789

Martus HJ, **Frötschl R**, Gollapudi B, Honma M, Marchetti F, Pfuhrer S, Schoeny R, Uno Y, Yauk C, Kirkland DJ (2020) Summary of major conclusions from the 7th International Workshop on Genotoxicity Testing (IWGT), Tokyo, Japan.

Mutat Res 852:503134

Marx U, Akabane T, Andersson TB, Baker E, Beilmann M, Beken S, **Brendler-Schwaab S**, Cirit M, David R, Dehne EM, Durieux I, Ewart L, Fitzpatrick SC, Frey O, Fuchs F, Griffith LG, Hamilton GA, Hartung T, Hoeng J, Hogberg H, Hughes DJ, Ingber DE, Iskandar A, Kanamori T, Kojima H, Kuehnl J, Leist M, Li B, Loskill P, Mendrick DL, Neumann T, Pallocca G, Rusyn I, Smirnova L, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tsyb S, Trapecar M, Van de Water B, Van den Eijnden-van Raaij J, Vulto P, Watanabe K, Wolf A, Zhou X, Roth A (2020) Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development.

ALTEX 37(3):365-394

Mehta M, Blume H, Beuerle G, Tampal N, Schug B, **Potthast H**, Jiang W, Wilson C (2020) The global bioequivalence harmonisation initiative: Report of EUFEPS/AAPS third conference.

Eur J Pharm Sci 151:105383, doi:10.1016/j.ejps.2020.105383

Michaleas S, Penninga E, Hovgaard D, Dalseg AM, Rosso A, Sarac SB, Jimenez JC, Fernández LL, Fernández CP, Mangas-SanJuan V, Garcia I, Payares-Herrera C, Sancho-López A, **Enzmann H**, de Castro Lopes Silva MSS, Duarte S, Pignatti F (2020) EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.

Oncologist 25(12):1067-1074



Moscetti L, Hennik P, Bolstad B, Camarero J, Josephson F, Melchiorri D, Sommerfelt Grønvold M, Sjoberg J, Botezatu M, Mulder J, Meulendijks D, Trullas Jimeno A, Zafiroopoulos N, Bergh J, **Enzmann H**, Pignatti F (2020) Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects.
ESMO Open 5(4): art. no. e000856

Niebank M, **Lehnert R**, Klug B, Wolf T (2020) COVID-19 - Anwendung antiviraler Arzneimittel.
Dtsch Arztebl 117(19):A1014-1015

Starokozhko V, Kallio M, Kumlin Howell Å, Mäkinen Salmi A, Andrew-Nielsen G, Goldammer M, Burggraf M, **Löbker W**, **Böhmer A**, Agricola E, de Vries CS, Pasmooij AMG, Mol PGM (2020) on behalf of the STARS consortium: Strengthening regulatory science in academia: STARS, an EU initiative to bridge the translational gap.
Drug Discov Today <https://doi.org/10.1016/j.drudis.2020.10.017>, online ahead of print

Tzogani K, Penttilä K, Lapveteläinen T, Hemmings R, **König J**, Freire J, Márcia S, Cole S, Coppola P, Flores B, Barbachano Y, Roige SD, Pignatti F (2020) EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
Oncologist 25(9):e1414-e1420

Tzogani K, Røshol H, Olsen HH, Aas IB, Dalhus ML, Håkonsen GD, Nilssen LS, Lindberg V, Okvist M, Bolstad B, Rogovska I, Karpova N, **Enzmann H**, Gisselbrecht C, Pignatti F (2020) The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
Oncologist 25(7):e1070-e1076

van der Laan JW, Benson CT, Janssens W, Bos J, **Stahl E**, Brady JT, Wändel-Liminga U, Corriol-Rohou S, Forster R, Hartmann A, Pertel PE, Robertson SM, Silva-Lima B, Malik RE, Chibout SD (2020) Shared Learnings on the New EMA First-in-Human and Early Clinical Trial Guideline: Proceedings From a DIALOGUE Session at DIA Europe 2018.
Ther Innov Regul Sci 54(2):462-467

Vreman RA, de Ruijter AS, Zawada A, Tafuri G, Stoyanova-Beninska V, O'Connor D, **Naumann-Winter F**, **Wolter F**, Mantel-Teeuwisse AK, Leufkens HGM, Sidiropoulos I, Larsson K, Goettsch WG (2020) Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations.
Drug Discov Today 25(7):1223-1231



Wolff-Holz E, **Weise M** (2020) Biosimilars in der EU: Bestandsaufnahme und neue Herausforderungen.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63(11):1365-1372

Yauk CL, Harrill AH, Ellinger-Ziegelbauer H, van der Laan JW, Moggs J, **Frötschl R**, Sistare F, Pettit S (2020) A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies.

Regul Toxicol Pharmacol 110:104526

Sonstige Publikationen

Bick N, Sachs B (2020) Cyproteronacetat: Meningeomrisiko führt zu weiteren Anwendungseinschränkungen.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 2:4-9

Cremer-Schaeffer P, Sommer C (2020) Langzeitanwendung von Opioiden bei chronischen nicht tumorbedingten Schmerzen (LONTS 3) [Editorial].

Schmerz 34(3):200-203

Dimitrova G (2020) Rote-Hand-Briefe und Informationsbriefe – der Weg von der Entstehung bis zur Versendung an den Empfänger.

Arzneiverordnung in der Praxis 47(3-4):113-117

Frötschl R, Haas B, Weise M (2020) Umgang mit Arzneimittelrisiken am Beispiel von Nitrosaminen – Teil 2: toxikologische Bewertung.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 3:11-16

Geller J (2020) Erfolgreicher Auftakt - Wie läuft die Versorgung von Patienten mit Hämophilie-Arzneimitteln in den Apotheken?

Dtsch Apoth Ztg 160(44):62

Glässner A, Krämer C, Yazdi A, Nöthen M, Sickmann A, Sachs B (2020) Forschungsprojekt INA: Analyse differenzieller Gen- und Proteinexpression zum In-vitro-Nachweis einer Arzneimittelallergie.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 2:29-32

Holtkamp F, Gudmundsdottir H, Maciulaitis R, **Benda N**, Thomson A, Vetter T (2020) Change in Albuminuria and Estimated GFR as End Points for Clinical Trials in Early Stages of CKD: A Perspective From European Regulators [Editorial].

Am J Kidney Dis 75(1):6-8



Meier T, Brohmann H, Sachs B, Scholl C (2020) Small interfering RNA (siRNA) als Arzneimittel: Wirkprinzipien und Effekte.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 4:10-21

Sasaki JC, Allemang A, Bryce SM, Custer L, Dearfield KL, Dietz Y, Elhajouji A, Escobar PA, Fornace AJ Jr., **Frötschl R**, Galloway S, Hemmann U, Hendriks G, Li HH, Luijten M, Ouedraogo G, Peel L, Pfuhler S, Roberts DJ, Thybaud V, van Benthem J, Yauk CL, Schuler M (2020) Application of the adverse outcome pathway framework to genotoxic modes of action [Commentary].

Environ Mol Mutagen 61(1):114-134

Schuessler-Lenz M, **Enzmann H**, Vamvakas S (2020) Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia [Commentary].

Clin Pharmacol Ther 107(3):492-494

Stephan K (2020) Pharmakovigilanz-Inspektionen – Fragebogen des BfArM und des PEI zur risikobasierten Inspektionsplanung.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 4:22-26

Urbach Y (2020) Blut - ein ganz besonderer Saft.

PZ Prisma 27(1):5-11

Wiesner J, Reh K, Knöss W (2020) Regulatorische Aspekte zu PA-Kontaminationen in Arzneipflanzen.

Journal für Kulturpflanzen 72(4):84-87

Wittenberg I, Frizler M, Leutenantsmeyer T, Grüger T, Palissa H (2020) Der Risikomanagementplan: Neufokussierung durch die zweite Revision des Moduls V des EU-Leitfadens zur Guten Pharmakovigilanzpraxis.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 2:20-28

Wittstock M, Jenniches I, Dussa J (2020) Umgang mit Arzneimittelrisiken am Beispiel von Nitrosaminen.

Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI 1:4-8



Bücher/Buchbeiträge

Aithal G, Andrade R, Avigan M, Benkritly A, Björnsson E, Bortolini M, Fontana R, Geary S, Kiazand A, Kullak-Ublick G, LeLouet H, Lucena M, Mao Y, Marcinak J, Merz M, Oster M, Pal S, Qiu X, Rágo L, Regev A, Sauer J, **Schabel E**, Soares M, Song H, Southern J, Straus W, Takikawa H, Tanaka D, Thörn M, Uzu S, Vidal J, Waksman J, Wang J, Zahng H (2020) Drug-Induced Liver Injury (DILI): Current Status and Future Directions for Drug Development and the Post-Market Setting. A consensus by a CIOMS Working Group. Council for International Organizations of Medical Sciences (CIOMS). World Health Organisation (WHO), Geneva, Switzerland

Glaeske G, **Broich K**, Dicheva-Radev S, Fuchs D, **Haberkamp M**, Hinneburg I, Höfel F, Kirschner J, **Löbker W**, Lübs A, Morawetz A, Muth L, **Naumann-Winter F**, Richter L, Ritter S, Sauer K, Schindler B (2020) Innovationsreport 2020 - Auswertungsergebnisse von Routinedaten der Techniker Krankenkasse aus den Jahren 2017 bis 2018. Herausgeber: Prof. Dr. Gerd Glaeske

Kösling AM (2020) Schutz vor Täuschung, § 8 AMG (Irreführungsverbot). In: Fuhrmann S, Klein B, Fleischfresser A (Hrsg) Arzneimittelrecht - Handbuch für die pharmazeutische Rechtspraxis, 3. Auflage. Nomos Verlagsgesellschaft, Baden-Baden, 627-642

Kösling AM, Wolf S (2020) § 11 Änderungen von Arzneimitteln nach der Zulassung, Variations, Mitteilungspflichten gem. § 29 AMG. In: Fuhrmann S, Klein B, Fleischfresser A (Hrsg) Arzneimittelrecht - Handbuch für die pharmazeutische Rechtspraxis, 3. Auflage. Nomos Verlagsgesellschaft, Baden-Baden, 456-477

Löbker W, **Broich K** (2020) Zulassung und Zusatznutzenbewertung von Arzneimitteln - Konflikte und potenzielle Lösungsansätze. In: Tunder R (Hrsg) Market Access Management für Pharma- und Medizinprodukte: Instrumente, Verfahren und Erfolgsfaktoren. Springer Gabler, Springer Fachmedien Wiesbaden GmbH, 201-215